1. Introduction {#s0005}
===============

Sudden cardiac death (SCD) is a major public health problem responsible for more than 300,000 deaths in the United States on an annual basis [@bb0005], [@bb0010], [@bb0015]. Implantable defibrillators are effective in treating malignant tachyarrhythmias but their impact in primary prevention of SCD could be significantly enhanced by improvements in risk stratification [@bb0020], [@bb0025], [@bb0030], [@bb0035]. Early studies highlighting a genetic contribution to pathophysiology of SCD [@bb0040], [@bb0045], [@bb0050], [@bb0055] prompted multiple candidate-gene based studies and genome wide association studies (GWAS) [@bb0060], [@bb0065]. As a result, several new loci associated with increased risk of SCD were identified from candidate gene based studies [@bb0070], [@bb0075], [@bb0080], [@bb0085], [@bb0090], [@bb0095], [@bb0100]. From GWAS studies, DNA variants within the BAZ2B [@bb0105] and CXADR [@bb0110] loci have passed the stringent GWAS significance threshold. However, independently, most of these loci contribute modestly to disease risk. In this study, we selected and investigated the contribution of common variants associated with SCD by published GWAS and candidate gene approaches. We also evaluated variants associated with intermediate electrical phenotypes (endophenotypes), specifically QRS duration [@bb0115], heart rate [@bb0120] and QTc interval [@bb0125]. We hypothesized that a genetic risk score (GRS) comprised of genetic variants that had been previously associated with SCD or SCD electrical phenotypes would provide additional information on SCD risk prediction. To test this, we developed GRSs for each of these endophenotypes and tested their association with SCD, using a well characterized SCD sample from the Oregon Sudden Unexpected Death Study (Oregon-SUDS). As controls, we used subjects with coronary artery disease (CAD) from the Wellcome Trust Case Control Consortium Study (WTCCC), thus looking for variants that influence risk of SCD in individuals with CAD, constituting the most common form of SCD.

2. Methods {#s0010}
==========

2.1. Ethics statement {#s0025}
---------------------

This study was approved by the Institutional Review Boards of the Oregon Health and Science University, Cedars-Sinai Medical Center and all participant hospitals. The WTCCC Data Access Committee approved the use of the WTCCC data. All samples have been analyzed in accordance with the principles expressed in the Declaration of Helsinki. Written informed consent was obtained from all enrolled subjects.

2.2. Subjects {#s0030}
-------------

### 2.2.1. Oregon-SUDS {#s0035}

A total of 966 SCD cases of European descent from the Oregon-SUDS [@bb0130], [@bb0135], [@bb0140] with GWAS data available, were included in the study. The Oregon-SUDS is an ongoing prospective study of out-of-hospital SCD. Methods have been published in detail [@bb0130], [@bb0140]. Briefly, SCD cases were identified from the emergency medical response system, the medical examiner network and 16 local hospitals. All available medical records were obtained for each subject following the SCD event, providing a detailed lifetime clinical history for the purpose of phenotyping. SCD was defined as an unexpected pulseless condition of likely cardiac origin. If unwitnessed, SCD was defined as unexpected death within 24 h of having last been seen alive and in a normal state of health [@bb0015]. CAD was defined as 50% stenosis of a major coronary artery, physician report of past myocardial infarction (MI), history of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG); autopsy-identified CAD or MI by clinical data with any two of the following three: ischemic symptoms, positive troponins or CKMB; or pathologic Q waves on ECG. SCD cases with chronic terminal illnesses, known non-cardiac causes of SCD, traumatic deaths and drug overdose were excluded from the analysis.

### 2.2.2. WTCCC subjects {#s0040}

A total of 1926 coronary artery disease (CAD) subjects were included as the comparison (control) group. We used CAD subjects rather than population controls due to the significant overlap between SCD and CAD (CAD is diagnosed in at least 80% of overall SCD cases) [@bb0145]. This would maximize the chances of developing a GRS that would be specific for SCD. CAD status and diagnosis was validated by direct review of clinical notes. All subjects were of White European origin and further details of the WTCCC subjects were previously reported [@bb0150].

### 2.2.3. Genotyping and SNP selection {#s0045}

The Oregon-SUDs cases and the WTCCC controls were genotyped and imputed separately using Affymetrix 6.0 and 500 K arrays respectively. SNPs were selected based on information obtained from the NHGRI GWAS Catalogue [@bb0155] and literature review [@bb0070], [@bb0075], [@bb0080], [@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0120], [@bb0125]. We selected 55 independent SNPs previously identified in GWAS studies for SCD-related phenotypes with P = 5 × 10^− 8^, these include: QRS duration, QT interval, and heart rate. ([Table 1](#t0005){ref-type="table"} and [Supplementary Table 1](#ec0005){ref-type="supplementary-material"}). We also included 14 SNPs associated with SCD in previous GWAS and candidate gene studies [@bb0070], [@bb0075], [@bb0080], [@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105], [@bb0110]. Deviation from Hardy Weinberg equilibrium was not observed for any SNP in either cases or controls. Three SNPs with minor allele frequency less than 5% were excluded from further analyses. After quality control, 66 SNPs for the 4 traits were included. For imputed SNPs, we used the posterior continuous values between 0 and 2. A complete list of the investigated variants is provided in [Supplementary Table 1](#ec0005){ref-type="supplementary-material"}.Table 1Traits included for the genetic risk scores estimations.TraitsNo. of SNPsReferenceSCD[a](#tf0005){ref-type="table-fn"}1414--22QRS duration2423Heart rate1924QTc interval925[^1]

### 2.2.4. Statistical analysis {#s0050}

Separate GRSs were developed for SNPs previously associated with increased risk of SCD (14 SNPs), prolonged QRS duration (26 SNPs), QT interval (9 SNPs) and increased heart rate (18 SNPs). For each of these GRSs, a weighted GRS was calculated for each individual based on the number of risk alleles weighted by the standardized beta coefficients derived from the original GWAS studies. Genetic risk scores were tested for association by using logistic regression models implement in Golden Helix SNP and Variation Suite (Golden Helix, Bonzeman, MT, USA). The status (case--control) was used as the outcome variable and the GRS as the predictor variable. In addition, we analyzed associations between individuals in the lowest and highest quintiles for the GRS composed of SCD SNPs using logistic regression. Individuals in the highest quintile were classified as high risk. Analyses were adjusted for age and gender.

3. Results {#s0015}
==========

The mean ages of the subjects in the Oregon-SUDS and the WTCCC studies were 60.3 ± 9.4 and 49.7 ± 12.8 years respectively. Seventy two percent of SCD cases and 79.2% of CAD controls were male. SCD cases were relatively older than CAD controls and therefore we performed analyses using the complete sample size in the Oregon-SUDs (n = 966) as well as a sample size restricted to the same age range observed in WTCCC (n = 668); similar results were observed ([Table 2](#t0010){ref-type="table"}).Table 2Association of GRS with SCD associated phenotypes.966 cases/1926 controls[a](#tf0010){ref-type="table-fn"}668 cases/1926 controls[b](#tf0015){ref-type="table-fn"}PhenotypeN SNPsOR (95% CI)[c](#tf0020){ref-type="table-fn"}P-valueOR (95% CI)[c](#tf0020){ref-type="table-fn"}P-valueHeart rate180.59 \[0.24--1.41\]0.230.56 \[0.22--1.41\]0.22QTc interval91.01 \[0.49--2.09\]0.690.86 \[0.36--2.01\]0.73QRS duration261.04 \[0.87--1.24\]0.651.06 \[0.88--1.27\]0.51SCD[d](#tf0025){ref-type="table-fn"}141.17 \[1.05--1.29\]0.0021.16 \[1.05--1.29\]0.003[^2][^3][^4][^5]

3.1. Genetic risk score associations {#s0055}
------------------------------------

We investigated association of each of the weighted GRS in the merged Oregon-SCD cases and WTCCC CAD control dataset including a total of 2892 unrelated individuals.

The cumulative effects of 14 common variants previously involved in SCD was modestly associated with an increased risk (OR = 1.17, P = 0.002). The results remained significant after adjusting for multiple testing comparisons. The risk for SCD was 1.5 fold greater in the highest risk quintile when compared to the lowest risk quintile (OR = 1.46 \[1.11--1.92\]). Two DNA variants within Calsequestrin 2 (*CASQ2*), rs3010396 and RAB3 GTPase activating protein subunit 1 (*RAB3GAP1*), rs6730157 were individually associated with SCD risk (P \< 0.05). We did not observe significant associations for the GRS for SCD after including these SNPs as covariates. As an exploratory analysis, we also evaluated the cumulative risk of the two significantly associated SCD SNPs in this study, resulting in an increased risk for SCD (OR--2.43, P = 5.18 × 10^− 10^). The direction of the effect for rs3010396 within *CASQ2* and rs6730157 within *RAB3GAP1* was consistent with previous findings [@bb0085], [@bb0090]. We did not observe evidence for a multiplicative interaction between SNPs rs3010396 and rs6730157 along with the main effects (P = 0.57).

No evidence for association was observed with SCD for SNPs that determine electrocardiographic traits ([Table 2](#t0010){ref-type="table"}).

4. Discussion {#s0020}
=============

We evaluated cumulative risk of SCD by computing GRSs based on SNPs previously associated with SCD and SCD electrocardiographic endophenotypes (heart rate [@bb0160], QTc interval [@bb0165] and QRS duration) [@bb0170]. The contribution of other common DNA variants previously associated with SCD was also evaluated. The predictive properties of these GRSs were estimated in a well characterized SCD population-based study from the Oregon-SUDS and CAD individuals from WTCCC. No evidence for association was found between the genetic risk score for the three electrocardiographic traits and SCD risk. This is in line with the evidence from previous observations. A recent study conducted in the Finnish population showed an association between common QTc interval variants and SCD, but no significant linear relationship between the genetic risk score for QTc interval and SCD was observed [@bb0175]. Although the Finnish study was conducted in large population-based cohorts, only 116 SCD cases were included.

The evaluation of the cumulative effects of common variants associated with SCD showed a modest increase in SCD risk (OR = 1.17 \[1.05--1.29\], P--0.002). We observed that two SNPs (rs3010396 and rs6730157) were individually associated with SCD (P \< 0.05). The results did not remain significant after adjusting for rs3010396 and rs6730157. This finding suggests that the genetic risk score for SCD was principally driven by SNPs rs3010396 and rs6730157. Interestingly, the combination of two common SNPs within *CASQ2* and *RAB3GAP1* significantly increased the odds for SCD risk (OR = 2.43, P = 7.41 × 10^− 10^). It is important to note that both SNPs were previously associated with an increased risk of SCD using a subset of SCD cases from the Oregon-SUDS and CAD individuals as the comparison group [@bb0085], [@bb0090].

What is the significance of these modest cumulative effects of published common variants, on risk of SCD? Clearly, the relatively small size of these effects is not likely to make a significant impact on the process of SCD risk stratification. In current clinical practice, the vast majority of SCD risk assessment is carried out using clinical criteria. In most patients the only clinical criterion is the measurement of the left ventricular ejection fraction, now recognized to be inadequate as a risk assessment tool [@bb0015], [@bb0180]. Therefore given the current modest state of SCD risk prediction and its overall impact on SCD prevention, it remains important to pursue the potential contributions of genetic testing to SCD risk stratification. As a proof of concept, we opted to assess the potential for cumulative effects on risk, of the multiple SNPs that were associated with SCD from GWAS and candidate-gene based approaches. This will also offer the possibility of combining clinical and genetic assessment to improve SCD risk stratification. There are several factors to suggest that our current analysis is likely to represent the first, albeit somewhat crude attempt at making this assessment. Candidate gene based approaches and GWAS have significant limitations as tools for comprehensive and unbiased identification of gene variants, and next generation sequencing approaches are designed to resolve these limitations. Therefore, with the help of current tools, we are likely to identify a more complete list of relevant SCD-associated gene variants.

The large majority of SCD occurs in individuals who are currently assessed as being at low or moderate risk. The question is, are we using the right tools for risk assessment? While this is a difficult question to answer at present, one of the potential tools could be a more complete identification of genetic variation using next generation sequencing in patients who are classified based on subset of risk. It would be particularly important to evaluate patients that were originally deemed to be low or moderate risk. This aspect highlights the potentially important role for studies like the present one that can identify these apparently low to moderate risk subsets, but all of them eventually suffered SCD. Another important aspect relates to the need for more intensive phenotyping in larger populations of patients who have suffered SCD. While a complete discussion is beyond the scope of this paper, it is likely that a step-wise approach will be needed. For example, identification of high-risk subjects in a community study or cohort study would lead to development of risk scores which in turn would be tested in prospective long term follow-up studies of defibrillators patients, in order to develop clinically useful risk scores. For genetic assessment, next generation genotyping needs to be performed and compared in high-risk population subsets of SCD based on intensive phenotyping. The expanding networks of SCD investigation will make it possible to identify these subgroups of enriched phenotypes. This will also offer the possibility of combining clinical and genetic assessment to improve SCD risk stratification.

Several limitations of the present study need to be considered. The sample size is small compared with the discovery GWAS studies and therefore lower statistical power may account for the absence of association observed for the investigated traits. The possibility remains that the investigated variants included in this study are not the actual causal variants. Also, we cannot exclude the potential confounding of electrical phenotype measurements by prescription or other medications. Finally, we were unable to test these same GRSs in a different population with a comparable level of detailed phenotyping and therefore these findings should be validated in additional populations.

In conclusion, we present proof of concept of the additive effect of gene variants on risk of SCD. A modest but significant association was found for the GRS composed of 14 previously associated SCD SNPs identified by GWAS. Next generation sequencing studies in larger samples of well-phenotyped subjects, are likely going to be needed for the identification of a clinically relevant cumulative genetic risk score for SCD.

The following is the supplementary data related to this article.Supplemental Table 1List of SNPs investigated in the present study.
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[^1]: Sudden cardiac death.

[^2]: Results including 966 SCD cases and 1926 controls from the WTCCC.

[^3]: Results including a subset of 668 SCD cases (age range 26--67 years) and 1926 controls from the WTCCC.

[^4]: OR indicates Odds ratio (95% confidence interval) per weighted allele increase in the GRS for each investigated trait. Data was adjusted by age and gender.

[^5]: Sudden cardiac death.
